SCHEMBL6325754

SCHEMBL6325754

COCCNCc1ccc(N)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.67
HTR2A P28223 2/20 0.49
CHRM2 P08172 2/20 0.44
CHEK1 O14757 1/20 0.44
HTT P42858 1/20 0.44
ANPEP P15144 1/20 0.44
ERAP2 Q6P179 1/20 0.44
DRD4 P21917 2/20 0.42
RAD52 P43351 1/20 0.41
PAX8 Q06710 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40
TBK1 Q9UHD2 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857148 0.89 L3MBTL1 (0.54) L3MBTL1HTR2ACHRM2ANPEPERAP2
SCHEMBL8252520 0.82 L3MBTL1 (0.64) L3MBTL1CHRM2CHEK1HTTDRD4
SCHEMBL12317 0.82 L3MBTL1 (0.64) L3MBTL1HTR2ACHRM2HTTDRD4
SCHEMBL10223307 0.81 L3MBTL1 (0.97) L3MBTL1CHRM2HTTTDP1KDM4E
SCHEMBL11304095 0.81 L3MBTL1 (0.67) L3MBTL1HTR2ACHRM2HTTTDP1
SCHEMBL9156034 0.81 L3MBTL1 (0.62) L3MBTL1CHRM2HTTDRD4RAD52
SCHEMBL2312495 0.81 CHRM2 (0.68) L3MBTL1HTR2ACHRM2HTTANPEP
SCHEMBL1241301 0.81 L3MBTL1 (0.62) L3MBTL1HTR2ACHRM2HTTRAD52
SCHEMBL2051245 0.81 L3MBTL1 (0.62) L3MBTL1CHRM2CHEK1HTTDRD4
SCHEMBL27721311 0.80 L3MBTL1 (0.53) L3MBTL1HTR2ACHRM2ANPEPERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed
EP-1115704-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES Boehringer Ingelheim Pharma KG (DE) 2001-07-18 EP disclosed
WO-2000018734-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 457/4885HTR2A 1943/4885CHRM2 583/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 505/4885HTR2A 1811/4885CHRM2 784/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK L3MBTL1 457/4885HTR2A 1943/4885CHRM2 583/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK L3MBTL1 485/4885HTR2A 1657/4885CHRM2 753/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK L3MBTL1 485/4885HTR2A 1657/4885CHRM2 753/4885
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 L3MBTL1 3701/4885HTR2A 1177/4885CHRM2 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.